User:Mr. Ibrahem/Tecovirimat

Mr. Ibrahem/Tecovirimat
Clinical data
Trade names	Tpoxx
Other names	ST-246
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name N-{3,5-Dioxo-4-azatetracyclo[5.3.2.0{2,6}.0{8,10}]dodec-11-en-4- yl}-4-(trifluoromethyl)benzamide;
Chemical and physical data
Formula	C19H15F3N2O3
Molar mass	376.335 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O;
	InChI InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25) ; Key:CSKDFZIMJXRJGH-UHFFFAOYSA-N ;

Tecovirimat, sold under the brand name Tpoxx, is an antiviral medication with activity against smallpox.^[3] Other uses may include monkeypox, cowpox, and complications of smallpox vaccination.^[2] It is taken by mouth.^[3]

Common side effects include nausea, headache, and abdominal pain.^[3] No serious side effects have been seen.^[4] It works by blocking orthopoxvirus VP37 protein, which prevents the virus from leave a cell.^[3]

Tecovirimat became the first drug approved for use in smallpox in the United States in 2018.^[5] Two million doses are in the US Strategic National Stockpile in the event that smallpox reoccurs.^[6] As of 2021 it is not approved in Europe.^[2]

References[edit]

^ "U.S. Food and Drug Administration Approves SIGA Technologies' TPOXX (tecovirimat) for the Treatment of Smallpox - SIGA". SIGA. Archived from the original on 21 September 2018. Retrieved 1 July 2021.
^ ^a ^b ^c "Tecovirimat". SPS - Specialist Pharmacy Service. 17 July 2018. Archived from the original on 31 July 2020. Retrieved 24 September 2021.
^ ^a ^b ^c ^d ^e ^f "Tecovirimat Monograph for Professionals". Drugs.com. Archived from the original on 28 November 2021. Retrieved 24 September 2021.
^ McNeil Jr DG. "Drug to Treat Smallpox Approved by F.D.A., a Move Against Bioterrorism". The New York Times. Archived from the original on 28 March 2019. Retrieved 16 July 2018.
^ Bonville, Cynthia; Domachowske, Joseph (2021). "28. Smallpox". In Domachowske, Joseph; Suryadevara, Manika (eds.). Vaccines: A Clinical Overview and Practical Guide. Switzerland: Springer. p. 337. ISBN 978-3-030-58416-0. Archived from the original on 3 June 2022. Retrieved 1 June 2022.
^ Cunningham A (13 July 2018). "FDA approves the first smallpox treatment". Archived from the original on 12 July 2018. Retrieved 1 July 2021.

[1] "U.S. Food and Drug Administration Approves SIGA Technologies' TPOXX (tecovirimat) for the Treatment of Smallpox - SIGA". SIGA. Archived from the original on 21 September 2018. Retrieved 1 July 2021.

[SPS2021-2] "Tecovirimat". SPS - Specialist Pharmacy Service. 17 July 2018. Archived from the original on 31 July 2020. Retrieved 24 September 2021.

[AHFS2021-3] ^ ^a ^b ^c ^d ^e ^f "Tecovirimat Monograph for Professionals". Drugs.com. Archived from the original on 28 November 2021. Retrieved 24 September 2021.

[NYT2018-4] McNeil Jr DG. "Drug to Treat Smallpox Approved by F.D.A., a Move Against Bioterrorism". The New York Times. Archived from the original on 28 March 2019. Retrieved 16 July 2018.

[Domachowske2021-5] Bonville, Cynthia; Domachowske, Joseph (2021). "28. Smallpox". In Domachowske, Joseph; Suryadevara, Manika (eds.). Vaccines: A Clinical Overview and Practical Guide. Switzerland: Springer. p. 337. ISBN 978-3-030-58416-0. Archived from the original on 3 June 2022. Retrieved 1 June 2022.

[6] Cunningham A (13 July 2018). "FDA approves the first smallpox treatment". Archived from the original on 12 July 2018. Retrieved 1 July 2021.

[1]

[3]

[2]

[4]

[5]

[6]